Jones Day
Standing out in particular for its activity in the private equity and venture capital spaces, the team at Jones Day is also well-versed in strategic M&A, handling a large volume of life sciences transactions in addition to advising on strategic partnerships and joint ventures, fundraising, and start-up financing matters. The practice is also noted for its cross-border capabilities, frequently working across the firm’s international offices to advise on the Belgian regulatory dimensions of multijurisdictional matters. Practice head Thomas De Muynck is described as possessing ‘unparalleled legal acumen’ and chiefly advises on private equity deals in the life sciences sector. Jonas Van Den Bossche is noted for his expertise in the chemicals sector, while Paul Van Hooghten advises on a wide array of corporate restructuring and M&A matters.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Thomas de Muynck and Steve Nuyts are knowledgeable, available, patient, nice, and always keep their calm, which is much appreciated in an M&A transaction. ’
‘What truly sets the Jones Day team apart is the exceptional talent and dedication of their team. Their attorneys, paralegals, and support staff bring a wealth of knowledge, experience, and passion to every case.’
‘When it comes to the individuals I've had the privilege of working with at Jones Day, they truly stand out as exceptional legal professionals.’
‘They understand our business and provide custom-made solutions that involve relevant specialists when needed.’
Key clients
- American Industrial Partners
- Arsenal Capital Partners
- Biobest Group
- Encevo
- Fortino Capital
- Hi Inov Capital
- iStar Medical
- Jensen-Group
- McCain Foods
- Pandox
- Partech Capital
- Rockley Management
- Specialized Bicycle Components
- The Riverside Company
Work highlights
- Advised iSTAR Medical SA on its strategic alliance with AbbVie for a value of up to $535m, a deal using the novel “option-to-acquire” structure.
- Advised Jensen-Group on the formation of a joint venture with MIURA whereby Jensen-Group acquired 49% of the shares of Inax Corporation and MIURA acquired a 20% stake in Jensen-Group.
- Advised Biobest Group NV on its capital increase in an amount of €98.5m, subscribed by Sofina SA and other private investors.
Lawyers
Next Generation Partners
Practice head
The lawyer(s) leading their teams.
Thomas De Muynck